Bio-Matrix Scientific Group, Inc., through its majority owned subsidiary, Regen BioPharma, Inc., intends to engage primarily in the development of regenerative medical applications. The company intends to license from other entities up to the point of completion of Phase I and or Phase II clinical trials after which it would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. Principal Products and Services HemaXellarate I The company has begun development of HemaXellerate I, a cellular therapy designed to heal damaged bone marrow. HemaXellerate I is a patient-specific composition of cells that have been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. The initial application of HemaXellerate I would be the treatment of severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia (underdevelopment or incomplete development of a tissue) and pancytopenia (reduction in the number of blood cells and platelets). HemaXellerate II Also in early stage development by the company is a version of HemaXellerate called HemaXellerate II.
bio-matrix scientific group
4700 Spring Street
La Mesa, CA 91942
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for BMSN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact BIO-MATRIX SCIENTIFIC GROUP, please visit www.regenbiopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.